Study guide

3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance

Key Takeaways Explain This Topic AI

Analgosedation (analgesia-first sedation) prioritizes opioid-based pain relief before adding hypnotic sedatives, optimizing patient comfort and lowering overall sedative requirements.

Paralyzing an intubated patient without providing adequate continuous sedation and analgesia causes severe psychological trauma and dangerous sympathetic surges.

Target sedation levels must be titrated using validated clinical scales: Richmond Agitation-Sedation Scale (RASS target -2 to -3) and Behavioral Pain Scale (BPS target < 5).

Propofol continuous infusions (5–50 mcg/kg/min) allow rapid neuro assessments but risk Propofol Infusion Syndrome (PRIS: metabolic acidosis, rhabdomyolysis, cardiac failure) at doses >4 mg/kg/hr or duration >48 hrs.

Dexmedetomidine (0.2–1.5 mcg/kg/hr) provides selective alpha-2 agonist cooperative sedation without respiratory depression, though bradycardia and hypotension are common side effects.

Last updated: July 2026

Post-Intubation Sedation, Analgesia & Dissociative Maintenance

Securing the endotracheal tube is only the first step in emergency airway management. Once intubation is confirmed, critical care transport paramedics must immediately transition to post-intubation maintenance care. Endotracheal tubes, mechanical ventilation, and transport vibration cause significant pain, anxiety, and ventilator dyssynchrony. Providing structured analgosedation (analgesia-first sedation) is essential to ensure patient safety, maintain oxygenation, and prevent accidental extubation.

  • 1. Analgosedation Philosophy & Avoiding Awareness Under Paralysis
  • The Analgosedation Paradigm

Historical critical care practice relied heavily on hypnotic sedatives (e.g., midazolam or propofol) as primary post-intubation agents. Modern critical care transport guidelines mandate an analgesia-first approach . Endotracheal intubation is intensely painful. Treating pain first with continuous IV opioids significantly reduces agitation, lowers total sedative consumption, shortens mechanical ventilation duration, and decreases ICU delirium.

Prevention of Patient Awareness Under Neuromuscular Blockade

One of the most severe clinical errors in emergency care is allowing a patient's sedation to wear off while neuromuscular blockade persists. Neuromuscular blocking agents (rocuronium, vecuronium) provide zero sedation, analgesia, or amnesia .

If paralytic activity outlasts induction hypnosis (e.g., etomidate lasting 10 minutes while rocuronium lasts 60 minutes), the patient experiences total motor paralysis while fully conscious—a state of intense horror and psychological trauma leading to post-traumatic stress disorder (PTSD). Physiological indicators of awareness under paralysis include:

Unexplained sinus tachycardia and hypertension.

Lacrimation (tearing) and diaphoresis.

Mydriasis (pupillary dilation).

Sudden spikes in ventilator peak airway pressures due to chest wall muscle tension.

Rule of Practice: Never administer a long-acting neuromuscular blocker without immediately initiating a continuous analgesic and sedative infusion.

2. Objective Sedation & Pain Assessment Scales

Titration of post-intubation infusions must be guided by objective, validated scoring systems rather than arbitrary dose administration.

Richmond Agitation-Sedation Scale (RASS)

The RASS is a 10-point scale evaluating patient agitation and depth of sedation:

  • Score Term Description Clinical Action
  • +4 Combative Overly combative, violent, immediate danger to staff Increase sedation / analgesia rapidly
  • +3 Very Agitated Pulls at tubes/catheters, aggressive Increase sedation / analgesia
  • +2 Agitated Frequent non-purposeful movement, fights ventilator Titrate infusion upward
  • +1 Restless Anxious, apprehensive, movements not aggressive Evaluate pain; low-dose bolus
  • 0 Alert and Calm Spontaneously attentive, calm Maintain current regimen

-1 Drowsy Sustained awakening ( > 10 seconds >10\text{ seconds} > 10 seconds ) to voice Ideal for weaning/extubation

-2 Light Sedation Briefly awakens ( < 10 seconds <10\text{ seconds} < 10 seconds ) with eye contact to voice Target Transport Goal

  • 3 Moderate Sedation Movement/eye opening to voice, no eye contact Target Transport Goal
  • 4 Deep Sedation No response to voice; movement to physical stimulation Targeted for ARDS / Severe TBI
  • 5 Unarousable No response to voice or physical stimulation Targeted during active paralysis

Transport Target: Maintain most mechanical ventilation patients at a RASS of -2 to -3 . Deep sedation (RASS -4 to -5) is reserved for severe ARDS requiring prone positioning, status epilepticus, or active neuromuscular blockade.

Behavioral Pain Scale (BPS)

Used for assessing pain in uncommunicative, intubated patients based on three physiological domains (Score 3 to 12):

Facial Expression: Relaxed (1), Partially tightened (2), Fully tightened (3), Grimacing (4).

Upper Limbs: No movement (1), Partially bent (2), Fully bent with finger flexion (3), Permanently retracted (4).

Compliance with Ventilator: Tolerating movement (1), Coughing but tolerating (2), Fighting ventilator (3), Inability to control ventilation (4).

Clinical Target: BPS < 5 < 5 < 5 indicates adequate analgesia.

  • 3. Continuous Infusion Pharmacology
  • Fentanyl Citrate

Role: Primary Continuous Analgesic.

Continuous Infusion Dose: 25 − 100 mcg/hr 25 - 100\text{ mcg/hr} 25 − 100 mcg/hr (or 0.5 − 2.0 mcg/kg/hr 0.5 - 2.0\text{ mcg/kg/hr} 0.5 − 2.0 mcg/kg/hr ). Bolus doses of 25 − 50 mcg 25 - 50\text{ mcg} 25 − 50 mcg IV every 15 minutes for breakthrough pain.

Advantages: Hemodynamically stable, rapid onset, lacks histamine release (unlike morphine), does not cause hypotension in normovolemic patients.

Propofol (Diprivan)

Role: Primary Sedative-Hypnotic.

Continuous Infusion Dose: 5 − 50 mcg/kg/min 5 - 50\text{ mcg/kg/min} 5 − 50 mcg/kg/min (Titrate by 5 − 10 mcg/kg/min 5-10\text{ mcg/kg/min} 5 − 10 mcg/kg/min every 5 minutes to target RASS).

Advantages: Ultra-short lipophilic elimination half-life allows rapid awakening for serial neurological exams.

Adverse Effects: Profound arterial hypotension. Prolonged high-dose infusions ( > 4.0 mg/kg/hr > 4.0\text{ mg/kg/hr} > 4.0 mg/kg/hr or > 67 mcg/kg/min > 67\text{ mcg/kg/min} > 67 mcg/kg/min for > 48 hours > 48\text{ hours} > 48 hours ) can trigger Propofol Infusion Syndrome (PRIS) , characterized by metabolic acidosis, hyperkalemia, rhabdomyolysis, hepatomegaly, acute kidney injury, and refractory bradycardic cardiac failure.

Ketamine (Ketalar)

Role: Dissociative Analgesic & Sedative Infusion.

Continuous Infusion Dose: 0.5 − 2.0 mg/kg/hr 0.5 - 2.0\text{ mg/kg/hr} 0.5 − 2.0 mg/kg/hr (sub-anesthetic analgesic rate 0.15 − 0.3 mg/kg/hr 0.15 - 0.3\text{ mg/kg/hr} 0.15 − 0.3 mg/kg/hr ; dissociative rate > 1.0 mg/kg/hr > 1.0\text{ mg/kg/hr} > 1.0 mg/kg/hr ).

Advantages: Maintains systemic vascular resistance and blood pressure, acts as a potent bronchodilator, and reduces opioid requirements.

Indications: Severe asthma, COPD, septic shock, and patients with refractory pain.

Midazolam (Versed)

Role: Benzodiazepine Sedative Infusion.

Continuous Infusion Dose: 1 − 5 mg/hr 1 - 5\text{ mg/hr} 1 − 5 mg/hr (or 0.05 − 0.2 mg/kg/hr 0.05 - 0.2\text{ mg/kg/hr} 0.05 − 0.2 mg/kg/hr ). Bolus 1 − 2 mg 1 - 2\text{ mg} 1 − 2 mg IV for breakthrough agitation.

Disadvantages: Highly lipophilic with active metabolites (1-hydroxymidazolam) that accumulate in adipose tissue and renal impairment, leading to prolonged emergence times and higher rates of ICU delirium. Secondary choice behind propofol or dexmedetomidine.

Dexmedetomidine (Precedex)

Role: Selective α 2 \alpha_2 α 2 ​ -Adrenergic Agonist Sedative.

Continuous Infusion Dose: 0.2 − 1.5 mcg/kg/hr 0.2 - 1.5\text{ mcg/kg/hr} 0.2 − 1.5 mcg/kg/hr (Loading boluses of 1.0 mcg/kg 1.0\text{ mcg/kg} 1.0 mcg/kg over 10 minutes are generally avoided in transport due to transient hypertension followed by severe bradycardia).

Mechanism: Acts on pre-synaptic α 2 \alpha_2 α 2 ​ receptors in the locus coeruleus to decrease norepinephrine release, producing a unique "cooperative sedation" state where patients remain easily arousable to voice.

Advantages: No respiratory depression, reduces delirium, opioid-sparing.

Adverse Effects: Sinus bradycardia and hypotension.

Post-Intubation Maintenance Infusion Matrix

Agent Class Maintenance Dose Primary Clinical Role Key Adverse Effects

Fentanyl Opioid Agonist 25 − 100 mcg/hr 25-100\text{ mcg/hr} 25 − 100 mcg/hr First-line analgesia Chest wall rigidity (high-dose bolus), respiratory depression

Propofol GABA-A Agonist 5 − 50 mcg/kg/min 5-50\text{ mcg/kg/min} 5 − 50 mcg/kg/min Rapidly titratable sedation Hypotension, hypertriglyceridemia, PRIS

Ketamine NMDA Antagonist 0.5 − 2.0 mg/kg/hr 0.5-2.0\text{ mg/kg/hr} 0.5 − 2.0 mg/kg/hr Bronchodilating analgosedation Emergence reactions, hypersalivation

Midazolam Benzodiazepine 1 − 5 mg/hr 1-5\text{ mg/hr} 1 − 5 mg/hr Sedation, anti-seizure Tissue accumulation, ICU delirium, prolonged emergence

Dexmedetomidine α 2 \alpha_2 α 2 ​ -Agonist 0.2 − 1.5 mcg/kg/hr 0.2-1.5\text{ mcg/kg/hr} 0.2 − 1.5 mcg/kg/hr Cooperative sedation Sinus bradycardia, hypotension